Loading...
•
Dec 31, 2023
CorMedix Q4 2023 Earnings Report
CorMedix reported a net loss for the fourth quarter of 2023, driven by increased costs related to market research, pre-launch activities for DefenCath, and personnel expenses.
Key Takeaways
CorMedix Inc. reported its Q4 and full-year 2023 financial results, highlighting a net loss for the quarter driven by increased spending on DefenCath pre-launch activities and personnel. The company is preparing for the commercial launch of DefenCath in April 2024 and has seen significant inbound interest.
CorMedix recorded a net loss of $14.8 million, or $0.26 per share, for the fourth quarter of 2023.
Operating expenses for the fourth quarter of 2023 were $15.7 million.
The company anticipates a commercial launch of DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024.
Total cash, cash equivalents, and short-term investments amounted to $76.0 million as of December 31, 2023.
Forward Guidance
CorMedix anticipates the commercial launch of DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024, pending a timely implementation of TDAPA. The Company believes that it has sufficient resources to fund operations for at least twelve months from the issuance of its Annual Report on Form 10-K.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...